InMed Pharmaceuticals Inc. (INM) - Dilution Analysis

10-Q filing | 3.3M shares outstanding

8-K filing: InMed Pharmaceuticals Inc. amended preferred investment options with Sabby Volatility Warrant Master Fund, Ltd. and affiliates of H.C. Wainwright & Co., LLC, reducing the exercise price for common share subscriptions.

S-3 filing: InMed Pharmaceuticals Inc. may offer and sell up to $50,000,000 in any combination of common shares, preferred shares, and subscription rights.

10-Q filing | 2.8M shares outstanding

S-1 filing: This S-1 filing registers 3,904,726 common shares offered by a selling shareholder, consisting of shares issuable upon exercise of pre-funded warrants and preferred investment options.

8-K filing: InMed Pharmaceuticals Inc. completed a private placement, issuing pre-funded warrants to purchase 1,952,363 common shares and preferred investment options to purchase up to 1,952,363 common shares to a single institutional accredited investor for gross proceeds of approximately $5 million. ($10.0M proceeds)

10-Q filing | 1.1M shares outstanding

10-Q filing | 1.2M shares outstanding

S-1 filing: This is an S-1 filing for an equity line offering of common stock, where the company may elect to issue and sell shares to a selling shareholder under a SEPA, potentially receiving up to $10,000,000 in aggregate gross proceeds. The company will not receive any proceeds from the sale of common shares by the selling shareholder.

10-Q filing | 0.7M shares outstanding

10-K filing | 13.3M shares outstanding

10-Q filing | 8.4M shares outstanding

10-Q filing | 6.1M shares outstanding

10-Q filing | 5.3M shares outstanding

S-1 filing: This S-1 filing relates to the offer and resale by selling shareholders of up to 12,569,564 common shares of InMed Pharmaceuticals Inc.

8-K filing: InMed Pharmaceuticals Inc. completed a private placement involving the issuance of pre-funded warrants and preferred investment options, and exercised existing preferred investment options for common shares and new preferred investment options, resulting in gross proceeds of approximately $5.2 million. ($2.72M proceeds)

10-K filing | 3.3M shares outstanding

10-Q filing | 3.3M shares outstanding

10-Q filing | 3.3M shares outstanding

S-1 filing: S-1 filing for offering of 5,090,918 common shares by selling shareholders.

8-K filing: InMed Pharmaceuticals Inc. completed a private placement on November 21, 2022, issuing 150,000 common shares and pre-funded warrants to purchase 1,668,185 common shares to institutional accredited investors at $3.30 per share, resulting in gross proceeds of approximately $6.0 million. ($6.0M proceeds)

10-Q filing | 0.9M shares outstanding

S-1 filing: S-1 filing for an offering of 2,073,735 common shares by selling shareholders.

10-K filing | 0.9M shares outstanding

POS AM filing: The filing discusses a private placement of common shares and warrants, along with the cancellation of previously issued investment options.

POS AM filing: These Post-Effective Amendments are being filed to reflect that, pursuant to Rule 416(b), the number of Common Shares covered by the Registration Statements was decreased respectively, (1) from 2,050,000 to 82,000 shares and (2) from 6,139,727 to 245,590 shares, as a result of the Consolidation.

POS AM filing: These Post-Effective Amendments are being filed to reflect that, pursuant to Rule 416(b) the number of Common Shares covered by the Registration Statements was decreased respectively, (1) from 2,050,000 to 82,000 shares and (2) from 6,139,727 to 245,590 shares, as a result of the Consolidation.

POS AM filing: Private placement of 691,245 common shares and unregistered preferred investment options to purchase up to 1,382,490 common shares for gross proceeds of approximately US$6 million.

POS AM filing: Private placement of common shares and warrants to institutional investors.

8-K filing: InMed Pharmaceuticals Inc. completed a private placement on September 13, 2022, issuing 90,000 common shares, pre-funded warrants to purchase 601,245 common shares, and preferred investment options to purchase 1,382,490 common shares for gross proceeds of approximately $6.0 million. ($6.0M proceeds)

S-1/A filing: This S-1/A filing registers 7,575,756 common shares for resale by a selling shareholder, consisting of shares issuable upon exercise of pre-funded warrants and preferred investment options from a June 2022 private placement.

S-1 filing: This S-1 filing relates to the offering and resale by the selling shareholder of up to 7,575,756 common shares, consisting of shares issuable upon the exercise of pre-funded warrants and preferred investment options from a June 2022 private placement.

8-K filing: InMed Pharmaceuticals Inc. entered into Securities Purchase Agreements for the issuance and sale of 4,079,256 common shares (or pre-funded warrants) at $0.858 per share in a registered direct offering, and 1,748,250 common shares (or pre-funded warrants) at the same price in a concurrent private placement, along with investment options to purchase 5,827,506 common shares at $0.74 per share, with gross proceeds expected to be approximately $5 million.

10-Q filing | 14.2M shares outstanding

S-3 filing: This S-3 filing discusses common share purchase warrants issued in a prior private placement and the terms of their exercise, including the exercise price, expiration date, and anti-dilution protection.

8-K filing: InMed Pharmaceuticals Inc. amended the Common Stock Purchase Warrants, reducing the exercise price to $0.45 per share, shortening the expiration date to March 31, 2023, and allowing cashless exercise, and also amended the Purchase Agreement to allow variable rate transactions.

10-Q filing | 13.8M shares outstanding

S-3/A filing: InMed Pharmaceuticals Inc. is registering the issuance and sale of up to US$50,000,000 of its common shares, preferred shares, warrants, units, and subscription receipts from time to time on a delayed or continuous basis.

S-3 filing: InMed Pharmaceuticals Inc. is filing an S-3 to offer up to $50,000,000 of any combination of common shares, preferred shares, subscription rights, warrants, or units from time to time at prices and on terms to be determined at or prior to the time of the offering.

S-3 filing: The filing is an S-3 indicating the company may issue debt or equity securities in the future, including common shares, that could dilute shareholders. It also discusses potential adverse tax consequences and future sales of common shares by officers and directors.

10-Q filing | 14.1M shares outstanding

8-K filing: InMed Pharmaceuticals Inc. issued 2,050,000 common shares to BayMedica's equity and convertible debt holders in connection with the acquisition of BayMedica.

10-K filing | 9.4M shares outstanding

8-K filing: InMed Pharmaceuticals Inc. will issue 1.78 million common shares to BayMedica's equity and convertible debt holders as part of the acquisition of BayMedica. Additionally, warrants to acquire up to 1.6 million common shares will be issued.

S-1 filing: This S-1 filing outlines an offering of 8,072,654 common shares by a selling shareholder, including shares obtainable via warrants. The company will not receive proceeds from the sale of these shares but may receive approximately $11.5 million upon the cash exercise of warrants.

8-K filing: InMed Pharmaceuticals Inc. entered into a Securities Purchase Agreement for a private placement offering of approximately $12 million in securities, including common shares, pre-funded warrants, and warrants, with net proceeds estimated at $11 million to be used for pipeline development, business development, and working capital. ($2.65M proceeds)

10-Q filing | 7.5M shares outstanding

S-1 filing: This S-1 filing registers 1,743,000 common shares for resale by selling shareholders, including shares issued in a private placement and shares issuable upon the exercise of warrants. The company will not receive proceeds from the sale of shares by selling shareholders, but may receive approximately $3.4 million upon the cash exercise of the warrants.

10-Q filing | 7.0M shares outstanding

10-Q filing | 7.0M shares outstanding

S-1/A filing: This S-1/A filing from 2020-10-08 discusses a proposed offering where Roth Capital Partners and Brookline Capital Markets are acting as underwriters. The company has granted the representative the right to act as a placement agent or underwriter if the company makes an offering of equity or equity-linked securities prior to the fifteen month anniversary of the closing date of this offering if it provides minimum net proceeds of $5 million.

S-1/A filing: S-1/A filing related to a potential offering where Roth Capital Partners has the right to act as a placement agent or underwriter, subject to certain fee limitations and this offering providing minimum net proceeds of $5 million.

S-1/A filing: This is an S-1/A filing. The document discusses underwriting details, including expenses, indemnification, lock-up agreements, other relationships, price stabilization, short positions, and penalty bids.

S-1/A filing: This is an S-1/A filing with information about Roth Capital Partners acting as underwriter and regarding potential offerings of equity or equity-linked securities in the future.

S-1 filing: S-1 filing describing indemnification agreements with the underwriter, lock-up agreements for officers and directors, the underwriter's right to act as a placement agent or underwriter for future offerings, and price stabilization measures.